The European Commission (EC) has approved ozanimod for the treatment of adults with relapsing-remitting MS (RRMS) who have active disease based on clinical or imaging features.
Ozanimod is a sphingosine-1-phosphate (S1P) receptor modulator that works by trapping immune cells in lymph nodes. This prevents immune cells from entering the nervous system, where they can promote further inflammation and nerve cell damage.
The EC’s decision was based on results from two Phase 3 clinical trials, SUNBEAM and RADIANCE, which collectively enrolled more than 2,600 participants with RRMS or SPMS at 150 sites in more than 20 countries.
For more information visit https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia